Translating Genetic Insights by Optimizing Sickle Cell Therapies from Bench to Bedside to Achieve Clinical Success
12:00 pm - Tuesday 29th September 2026
- Anchoring preclinical programs on human genetic insights and the critical 60/40 hemoglobin ratio to optimize therapeutic development
- Optimizing therapeutic strategies by aligning preclinical endpoints with target product profiles to achieve meaningful clinical outcomes
- Achieving consistent 60/40 hemoglobin ratios in clinic, reducing painful vaso-occlusive crises to meet registrational endpoint
